BRC-002

Phase 1Small molecule

UUniversity of Colorado, Denver

BRC-002 is one of 9 small molecule programs targeting Complex Regional Pain Syndrome. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Complex Regional Pain SyndromeRecruiting

Complex Regional Pain SyndromePhase 1

Recruiting

Competition

Competitive Landscape

9 competitors in Complex Regional Pain Syndrome

#DrugCompanyPhaseTrials

Suboxone

IIndivior Inc.

Approved

1 2

Lyrica

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

1 3

Ketalar

AAultman Health Foundation

Approved

1 4

Aspercreme Warming

AAveritas Pharma, Inc.

Approved

—5

Neurontin

VViatris Specialty LLC

Preclinical

1 6

Botox

VVitae Pharmaceuticals Inc., an Allergan affiliate

Botox

BRC-002

UUniversity of Colorado, Denver

Phase 1

1 9

Optimizing the Medication

OOulu University Hospital

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 2Not yet recruiting

Restless Leg Syndrome

NCT07224932

Q2 2029

Phase 1Recruiting

Complex Regional Pain Syndrome

NCT06393101

Clinical

Trials by Indication[1]

Complex Regional Pain Syndrome1 trial

The Effects and Mechanisms of a High CBD Cannabis Extract (BRC-002) for the Treatment of Pain and Health in Complex Regional Pain Syndrome

Recruiting·UUniversity of California, San Diego·Phase 1·NCT06393101·52 enrolled

Restless Leg Syndrome1 trial

A Randomized, Double-blind, Placebo-controlled Parallel Study of the Tolerability and Efficacy of High Cannabidiol (CBD) Cannabis Extract for the Treatment of Patients With Idiopathic Restless Legs Syndrome (RLS)

Not yet recruiting·UUniversity of Colorado, Denver·Phase 2·NCT07224932·60 enrolled

Unspecified1 trial

A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose and Repeat Dose and Randomized, Open-label, Crossover, Food Effect Safety, Tolerability, and Pharmacokinetic Study of BRC-002 in Healthy Participants

Enrolling by invitation·BBiopharmaceutical Research Company·Phase 1·NCT07699120·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for BRC-002. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BRC-002 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BRC-002. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Colorado, Denver company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: UUniversity of Colorado, Denver

BRC-002

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Q2 2029

Trials by Indication[1]

Complex Regional Pain Syndrome1 trial

Restless Leg Syndrome1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News